The current Coronavirus disease 2019 or COVID-19 pandemic has infected over two million
people and resulted in the death of over one hundred thousand people at the time of writing …

Although most autoimmune diseases are considered to be CD4 T cell-or antibody-mediated,
many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma …

Importance Risk factors associated with the severity of coronavirus disease 2019 (COVID-
19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies …

Abstract Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target
immunity and have the potential to increase the risk of severe acute respiratory syndrome …

Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19
en establecimientos de atención de la salud. Recomendaciones basadas en consenso de …

Objective We systematically reviewed the literature on COVID-19 in patients with multiple
sclerosis (MS). Methods We searched PubMed, Scopus, EMBASE, CINAHL, Web of …

Abstract The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions
regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have …

Novel coronavirus (severe acute respiratory syndrome coronavirus-2: SARS-CoV-2) has a
high homology with other cousin of coronaviruses such as SARS and Middle East …

It has been suggested that some individuals may present genetic susceptibility to SARS‐
CoV‐2 infection, with particular research interest in variants of the ACE2 and TMPRSS2 …

Background COVID-19 vaccination is recommended for patients with multiple sclerosis
(pwMS), while disease-modifying therapies (DMTs) may influence the efficacy of SARS-CoV …